Investors + Media

Company Overview

Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.

View Leadership

Sign Up For E-Mail Alerts

Sign Up

Stock SnapshotView Detailed Stock Info

Sangamo Therapeutics, Inc.

Market/Symbol Nasdaq: SGMO
Market Cap
Day Range
52 WK Range

Quarterly Results

Q2 2018

Quarterly Results

Quarter Ended Jun 30, 2018
Annual Report

Latest 10-K + Proxy

IR Contact Information

Investor Relations

McDavid Stilwell
Corporate Communications
T: 510-970-6000 x219
F: 510-236-8951

Transfer Agent

Computershare, Inc.
250 Royall Street
Canton, MA 02021
T: 781-575-3951
F: 781-575-2152